Boehringer Ingelheim Acquires Abexxa Biologics To Further Expand Its Research Efforts In Cancer Immunology And Novel Immunotherapeutic Approaches
Boehringer Ingelheim Acquires Abexxa Biologics To Further Expand Its Research Efforts In Cancer Immunology And Novel Immunotherapeutic Approaches
09/21/21, 12:07 PM
Location
vancouver
Industry
sports
Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology research to develop the next generation of precision medicines designed to revolutionize cancer treatments. The acquisition will allow Boehringer Ingelheim to access Abexxa’s expertise in targeting cancer-specific proteins that are located inside the cell, rather than those expressed on the cell membrane. This enlarges the pool of potential cancer antigen targets. In particular, Abexxa’s technology could lead to the development of cancer immunotherapies that are effective in a broader range of patients and cancer types.